BC Extra | Jun 28, 2019
Politics & Policy

‘Product hopping’ under fire in Senate bill

When Allergan withdrew Alzheimer's disease drug Namenda memantine from the market so physicians would prescribe a reformulated once-daily version with a longer patent life, the company was engaging in an anticompetitive practice, according to Sen....
BioCentury | Apr 26, 2019
Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

By developing native and glycosylated forms of the angiotensin-(1-7) peptide for vascular cognitive impairment, ProNeurogen hopes to plug a treatment gap that repurposed Alzheimer's disease drugs have failed to fill. There are no therapies approved...
BC Week In Review | Feb 1, 2019
Financial News

Drug delivery company Lyndra raises $55M series B

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and...
BC Extra | Jan 29, 2019
Financial News

Drug delivery company Lyndra raises $55M series B

Lyndra Therapeutics Inc. (Watertown, Mass.) raised $55 million in a series B round to advance compounds delivered via its capsule platform. Polaris Partners led the round and was joined by all other original investors and...
BC Week In Review | Jan 5, 2018
Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
BC Extra | Jan 4, 2018
Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
BC Innovations | Dec 5, 2017
Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest NMDA receptor antagonists could help treat autism caused by MEF2C haploinsufficiency. In an MEF2C-haploinsufficient mouse model of autism, NitroSynapsin, a memantine-based NMDA receptor antagonist, increased total hippocampal neurons and decreased...
BC Extra | Nov 17, 2017
Preclinical News

Memantine-based NMDA receptor antagonist could help treat autism

A study published in Nature Communications identified myocyte enhancer factor 2C (MEF2C) mutations as a source of abnormal brain development and function and suggests an NMDA receptor antagonist could help treat autism. MEF2C regulates several...
BioCentury | Oct 28, 2017
Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
BC Week In Review | May 12, 2017
Company News

Adamas, HCR in $100M royalty deal

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) will receive a loan worth up to $100 million via a royalty note deal with HealthCare Royalty Partners (Stamford, Conn.). The company is to receive $35 million up front and $65...
Items per page:
1 - 10 of 291